Trial Profile
A pilot phase II trial of PSC 833 [valspodar] modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Valspodar (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Sep 2005 New trial record.